Halozyme Therapeutics HALO Net margin
Net margin at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Halozyme Therapeutics’s 10-Q, filed November 3, 2025, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's net margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's net margin?
- Halozyme Therapeutics (HALO) reported net margin of 47.9% in Q3 2025.
- How has Halozyme Therapeutics's net margin changed year-over-year?
- Halozyme Therapeutics's net margin increased by 15.7% year-over-year, from 41.4% to 47.9%.
- What is the long-term trend for Halozyme Therapeutics's net margin?
- Over 4 years (2020 to 2024), Halozyme Therapeutics's net margin has grown at a -2.4% compound annual growth rate (CAGR), from 48.2% to 43.7%.
- What does net margin mean?
- The share of every sales dollar that becomes bottom-line profit.
- How do you interpret net margin?
- Higher is better, but net margin mixes operating performance with financing and tax effects and one-off items — read it alongside operating margin to separate the operating story from the rest.
- How does net margin compare across companies?
- Comparable across peers but sensitive to leverage and tax structure; two operationally identical firms can show different net margins purely from financing.